Physician

Juan C Velazquez, MD

According to 2025 Medicare claims, Juan Velazquez, MD (NPI: 1497812895) practices family practice in the El Centro, CA market, with the plurality of this provider's patient population coming from Imperial, CA. This provider's primary affiliated billing organization is LEGACY MD MEDICAL GROUP INC (NPI: 1073210753; TIN: 88-4410340) and primary practice location at 92231-3211. Velazquez is affiliated with the Asaar Medical Inc. (ACO ID: D0071), participating under the REACH model.

Velazquez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,016 traditional Medicare patients, billed 9,226 HCPCS/CPT codes, and received $332,254 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 7,674 prescription claims across 1,007 beneficiaries totaling $756,773 in drug costs, led by Ozempic (Semaglutide). DME data shows 120 claims. Open Payments data shows 20 records totaling $622. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $6,347 to $332,254. In contrast, Part D prescription costs have moved from a higher plateau to a lower plateau, from $952,434 to $756,773. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $58,665 to $15,565.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	145	167	$6,347
2018	137	185	$3,670
2019	385	882	$11,509
2020	442	806	$23,052
2021	1,124	2,613	$131,493
2022	1,510	5,084	$268,113
2023	1,046	8,338	$297,637
2024	1,016	9,226	$332,254

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	553	18,888	$952,434
2016	552	22,545	$1,175,837
2017	621	20,043	$1,406,183
2018	639	17,690	$1,618,773
2019	643	17,374	$1,593,435
2020	655	10,357	$1,010,153
2021	734	4,505	$476,956
2022	1,113	8,131	$766,889
2023	1,172	8,563	$861,709
2024	1,007	7,674	$756,773

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	416	1,164	$92,992
2016	258	822	$21,446
2017	260	742	$23,181
2018	185	461	$3,191
2019	147	437	$6,974
2020	78	281	$8,121
2021	36	115	$1,561
2022	68	166	$1,386
2023	96	245	$5,142
2024	50	120	$10,889

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	421	733	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	779	2,109	$67
87811	Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19)	238	337	$41
87804	Detection test by immunoassay with direct visual observation for influenza virus	145	356	$16
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	244	378	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	80	2,824	$80,319
Farxiga	Dapagliflozin Propanediol	70	3,450	$61,223
Trulicity	Dulaglutide	41	1,400	$43,865
Januvia	Sitagliptin Phosphate	39	2,370	$39,498
Jardiance	Empagliflozin	34	1,860	$33,524

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	21	$10,151
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	32	71	$708
A4259	Lancets, per box of 100	N	18	28	$30

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$622	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Juan C. Velazquez, MD?

Tedicare shows public-source Medicare data for Juan C. Velazquez, MD (NPI 1497812895), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Juan C. Velazquez, MD have ACO affiliation data?

Juan C. Velazquez, MD is shown with ACO affiliation data for Asaar Medical Inc. (REACH, ACO ID D0071).

What billing organization is linked to Juan C. Velazquez, MD?

Juan C. Velazquez, MD is linked to LEGACY MD MEDICAL GROUP INC (billing NPI 1073210753) in the available physician profile data.

Does Juan C. Velazquez, MD have Open Payments data?

Juan C. Velazquez, MD has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.